Experts Contest Trump’s Credit Claim for Drug Price Drop

Debating the Credit for the Recent Decline in Prescription Drug Prices

Despite numerous claims from President Donald Trump and his administration attributing the recent reduction in prescription drug prices to their efforts, many experts remain doubtful. This skepticism is centered around the perceived limited impact of the deals struck with drug makers and the launch of TrumpRx, the online direct-to-consumer platform. These critics suggest that other factors are more likely responsible for the majority of the price drop.

Observations from the Trump Administration

In mid-August, the Bureau of Labor Statistics released consumer price data that showed a decrease in prescription drug prices of 3.1% over the past year. This drop led to quick celebrations from Trump and his allies. These data measure the prices paid by consumers and insurers at retail, internet, or mail-order pharmacies.

In a speech on Long Island on August 14, Trump cited his most-favored-nation policy on drug prices as a significant factor behind the price reduction. He repeated this claim during an event at the White House on August 31 where he announced additional deals with drug companies.

Furthermore, during an interview on CBS News’ “Face the Nation” on August 23, Administrator Mehmet Oz of the Centers for Medicare & Medicaid Services credited the price drop to the administration’s dealmaking and the launch of TrumpRx. This platform lists discounts on specific drugs for cash-paying consumers.

Expert Opinions on the Cause of the Price Drop

However, several experts in drug pricing have suggested that neither TrumpRx nor the agreements with drug companies are likely to have been the primary drivers behind the price drop. Instead, they point to other potentially more impactful factors such as market pressures driving down the cost of GLP-1 weight-loss drugs, the introduction of more generics to the market, and a policy from the Biden-era that allows Medicare to negotiate drug prices.

White House spokesman Kush Desai rejected the idea that Medicare price negotiations carried out during the Biden administration could have significantly impacted drug prices. He argued that Trump’s Most-Favored-Nations deals had a broader impact as they cover hundreds of drugs and claimed that TrumpRx.gov has already saved real patients over $700 million.

Uncertainty Surrounding the Impact of Drug Pricing Deals and TrumpRx

While there has been a significant one-year decline in prescription drug prices, as tracked by the Bureau of Labor Statistics’ Consumer Price Index, the actual impacts of the Trump administration’s drug pricing deals and TrumpRx are less clear. Since last July, prescription drug prices have dropped by 3.1%, marking the largest one-year decrease since 1963. Although Trump and other officials link this decrease to their deals with pharmaceutical companies, experts point out that the scope of these deals is limited.

Health economist Jeromie Ballreich from Johns Hopkins University said that TrumpRx is unlikely to have significantly impacted the overall prescription-drug market given its relatively small patient base. The White House claims that TrumpRx has saved Americans over $700 million, but they have not provided a detailed breakdown of how this figure was derived.

Other Possible Causes of the Price Drop

Experts suggest that the fall in prices for GLP-1 drugs due to increased competition and the introduction of new generics and biosimilars onto the market likely played a significant role in the overall decrease in drug prices. Another potential factor is a policy signed into law by President Joe Biden as part of the 2022 Inflation Reduction Act, which gave Medicare the authority to negotiate prices for certain expensive drugs.